Development of a scaleable, sustainable manufacutring process for a novel, high-value polypeptide

开发新型高价值多肽的可规模化、可持续的生产工艺

• 批准号: 131147
• 金额: $ 10.97万
• 依托单位: BIOCATALYSTS LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2013
• 资助国家: 英国
• 起止时间: 2013 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=131147
• 关键词: Development; scaleable; sustainable; manufacutring; process

Leukolectin is a novel, patented molecule, exhibiting (in pre-clinical tests) remarkable benefits for the treatment of a range of skin, autoimmune and gastrointestinal disorders. Leukolectin is absent in many disease states, suggesting that its presence is critical for preventing the listed ailments. By creating a range of topical and oral medicaments containing Leukolectin, Seagarden, a Norwegian company who manufacture seafood ingredients and marine bioactives, hope to dramatically improve the severity of symptoms experienced by millions of suffers around the World. The project will be facilitated by Biocatalysts Ltd, a UK enzyme developer and manufacturer, who have vast experience of large-scale manufacturing of proteins such as leukolectin. Production of leukolectin via fermentation will ensure that production costs of these medical nutrition products are kept to a minimum, and that leukolectin is produced using a sustainable and environmentally-friendly process.

Leukolectin是一种新的专利分子，在临床前测试中显示出对治疗一系列皮肤、自身免疫性和胃肠道疾病的显著益处。Leukolectin在许多疾病状态下都不存在，这表明它的存在对于预防列出的疾病至关重要。生产海鲜配料和海洋生物活性物质的挪威公司Seagarden，通过创造一系列含有白介素素的外用和口服药物，希望极大地改善全球数百万患者所经历的症状的严重程度。该项目将由英国酶开发商和制造商Biocatalysts Ltd推动，该公司在大规模制造白蛋白等蛋白质方面拥有丰富的经验。通过发酵生产白细胞凝集素将确保将这些医用营养产品的生产成本保持在最低水平，并确保使用可持续和环保的工艺生产白细胞凝集素。